Want to see PHG full AI Analyst Report?
Earnings Data
Report Date
Jul 28, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
0.4Last Year’s EPS
0.42Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
Overall the call presented a constructive tone: Philips reported broad-based order and sales growth, margin expansion, strong productivity delivery, robust innovation and regulatory momentum, and meaningful balance sheet improvement. These positives were balanced against notable headwinds in China (centralized procurement), cost inflation (freight, components, plastics) and near-term margin timing effects from tariffs and inflation. Management reiterated full-year guidance (3%–4.5% comparable sales; 12.5%–13% adjusted EBITDA margin; EUR 1.3–1.5bn free cash flow) and emphasized mitigation actions (productivity, selective pricing, AI-enabled cost savings) while acknowledging geopolitical and legal uncertainties.Company Guidance
Order Intake and Sales Growth
Order intake grew 6% in Q1 with equipment order intake up 6% and continued momentum across businesses. Group comparable sales increased ~3.7%–4% year-on-year (management cited both 3.7% and ~4%), with growth across all segments and regions led by North America and Western Europe.
Margin Expansion and Profitability
Adjusted EBITDA margin expanded by 40 basis points to 9.0% in Q1 (group). Segment margins: Diagnosis & Treatment adjusted EBITDA margin +30 bps to 9.8%, Personal Health margin +60 bps to 15.8%. Adjusted diluted EPS from continuing operations was EUR 0.23 (vs EUR 0.25 prior year). Net income rose to EUR 146 million.
Personal Health Outperformance
Personal Health delivered broad-based comparable sales growth of 9% in Q1, led by double-digit growth in North America. Distribution expansion: added >3,000 distribution points in Europe and increased retail listings. Strong consumables/recurring revenue: >50 million OneBlade handles and 100 million blades sold.
Productivity Delivery and Cost Discipline
Q1 product productivity delivered EUR 126 million toward the EUR 1.5 billion 3-year savings commitment; actions include SKU rationalization, supplier consolidation and AI-enabled efficiencies. Adjusting items materially reduced to EUR 61 million from EUR 143 million prior year.
Innovation and Regulatory Momentum
Received 20 510(k) clearances and PMAs in Q1 (more than double YoY). Notable clearances/launches: SmartHeart (AI cardiac MR), Verida spectral CT (initial European orders and first installation), DeviceGuide for Azurion, IntraSight Plus, helium-free MR leadership (BlueSeal >2,200 installs; >6 million liters of helium saved) and unveiled helium-free 3.0T targeting regulatory clearance in 2027.
Commercial & Clinical Partnerships
Signed strategic partnerships and enterprise agreements including a 5-year enterprise service agreement with AdventHealth and a multi-modality strategic partnership with WellSpan Health. Seven clinical studies underway for the interventional platform via a research consortium.
Improved Balance Sheet and Cash Flow
Ended Q1 with EUR 2.6 billion cash after a $265 million SpectraWAVE acquisition payment. Net debt EUR 5.5 billion and leverage improved to 1.8x (from 2.2x in Q1 2025). Free cash flow in Q1 was an inflow of EUR 28 million; excluding the prior-year Respironics settlement impact, free cash flow improved by EUR 94 million YoY.
Quality and Operational Improvements
Field actions reduced ~20% year-to-date (following ~40% reduction in 2025). Supply chain initiatives (regionalization/localization) maintained customer service levels despite Middle East volatility and supported resilience and reduced release cycle times by ~25% in some areas via AI-enabled testing.
PHG Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
PHG Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 06, 2026 | $25.61 | $26.36 | +2.95% |
Feb 10, 2026 | $28.68 | $31.86 | +11.11% |
Nov 04, 2025 | $26.34 | $27.13 | +2.98% |
Jul 29, 2025 | $24.84 | $27.13 | +9.20% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Koninklijke Philips N.V. (PHG) report earnings?
Koninklijke Philips N.V. (PHG) is schdueled to report earning on Jul 28, 2026, Before Open (Confirmed).
What is Koninklijke Philips N.V. (PHG) earnings time?
Koninklijke Philips N.V. (PHG) earnings time is at Jul 28, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PHG EPS forecast?
PHG EPS forecast for the fiscal quarter 2026 (Q2) is 0.4.
